- Home
- TLSA vs PLX Comparison
TLSA vs PLX Comparison
Compare TLSA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSA | PLX |
|---|---|---|
| Founded | 2013 | 1993 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.3M | 191.0M |
| IPO Year | 2017 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TLSA | PLX |
|---|---|---|
| Price | $0.94 | $2.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 258.9K | ★ 499.8K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.91 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $1.41 |
| 52 Week High | $2.60 | $3.19 |
Technical Indicators
Market Signals| Indicator | TLSA | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.65 | 53.49 |
| Support Level | N/A | $2.06 |
| Resistance Level | $1.45 | $2.44 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 13.90 | 41.30 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.